| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| C Houc. An open-label pilot study of fluvoxamine for mixed anxiety-depression. Psychopharmacology bulletin. vol 34. issue 2. 1998-07-14. PMID:9641005. |
fluvoxamine, a selective serotonin reuptake inhibitor (ssri) approved for the treatment of obsessive-compulsive disorder, was studied for its effectiveness in treating anxiety and depression simultaneously during an 8-week, open-label trial of patients with mad. |
1998-07-14 |
2023-08-12 |
Not clear |
| C A Stockmeie. Neurobiology of serotonin in depression and suicide. Annals of the New York Academy of Sciences. vol 836. 1998-06-24. PMID:9616801. |
neurobiology of serotonin in depression and suicide. |
1998-06-24 |
2023-08-12 |
human |
| C A Stockmeie. Neurobiology of serotonin in depression and suicide. Annals of the New York Academy of Sciences. vol 836. 1998-06-24. PMID:9616801. |
alterations in serotonin neurotransmission have been implicated in the pathophysiology of major depression and suicide. |
1998-06-24 |
2023-08-12 |
human |
| C A Stockmeie. Neurobiology of serotonin in depression and suicide. Annals of the New York Academy of Sciences. vol 836. 1998-06-24. PMID:9616801. |
altered signal transduction in cerebral cortex and altered regulation of serotonin neurons in the dr may be important in the pathophysiology of major depression and suicide. |
1998-06-24 |
2023-08-12 |
human |
| J Fawcett, K A Busch, D Jacobs, H M Kravitz, L Fog. Suicide: a four-pathway clinical-biochemical model. Annals of the New York Academy of Sciences. vol 836. 1998-06-24. PMID:9616805. |
this chapter, based on a review of recent research as well as data presented in this report, proposes four hypothetical pathways leading to suicide in clinical depression: (1) an acute pathway involving severe anxiety/agitation associated with high brain corticotrophin-releasing factor (crf or crh) levels, (2) trait baseline and reactivity hopelessness, (3) severe anhedonia, and (4) trait impulsiveness associated with low brain serotonin turnover and low total cholesterol as a possible peripheral correlate. |
1998-06-24 |
2023-08-12 |
Not clear |
| C C Meltzer, G Smith, S T DeKosky, B G Pollock, C A Mathis, R Y Moore, D J Kupfer, C F Reynold. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 18. issue 6. 1998-06-23. PMID:9571651. |
it has been further suggested that the age-related changes in 5-ht neurons may predispose the elderly to develop depression. |
1998-06-23 |
2023-08-12 |
human |
| P Moore, C Gillin, T Bhatti, A DeModena, E Seifritz, C Clark, S Stahl, M Rapaport, J Kelso. Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Archives of general psychiatry. vol 55. issue 6. 1998-06-23. PMID:9633672. |
rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. |
1998-06-23 |
2023-08-12 |
human |
| C Sur, H Betz, P Schlos. Distinct effects of imipramine on 5-hydroxytryptamine uptake mediated by the recombinant rat serotonin transporter SERT1. Journal of neurochemistry. vol 70. issue 6. 1998-06-05. PMID:9603221. |
tricyclic and nontricyclic serotonin [5-hydroxytryptamine (5-ht)] uptake inhibitors are widely used for the treatment of depression. |
1998-06-05 |
2023-08-12 |
rat |
| S D Silberstei. Comprehensive management of headache and depression. Cephalalgia : an international journal of headache. vol 18 Suppl 21. 1998-05-21. PMID:9533672. |
while tricyclic antidepressants may be more effective for migraine, selective serotonin reuptake inhibitors are just as effective for depression and have fewer side effects. |
1998-05-21 |
2023-08-12 |
Not clear |
| R A Furlong, L Ho, C Walsh, J S Rubinsztein, S Jain, E S Paykel, D F Easton, D C Rubinsztei. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. American journal of medical genetics. vol 81. issue 1. 1998-05-13. PMID:9514589. |
the serotonin transporter is a compelling candidate gene to examine in bipolar and unipolar affective disorder, since drugs that specifically inhibit the serotonin transporter can successfully treat depression. |
1998-05-13 |
2023-08-12 |
Not clear |
| T J Cleopha. Depression and myocardial infarction: implications for medical prognosis and options for treatment. The Netherlands journal of medicine. vol 52. issue 2. 1998-05-13. PMID:9557532. |
the selective serotonin reuptake inhibitors lack arrhythmogenic effects, and have a beneficial effect in addition to depression on psychological factors, such as anxiety and mood disturbances, which are not uncommon in post-mi patients. |
1998-05-13 |
2023-08-12 |
Not clear |
| b' N Pivac, M Jakovljevi\\xc4\\x87, D M\\xc3\\xbcck-Seler, Z Brzovi\\xc4\\x8. Hypothalamic-pituitary-adrenal axis function and platelet serotonin concentrations in depressed patients. Psychiatry research. vol 73. issue 3. 1998-04-30. PMID:9481804.' |
our results suggest that plasma cortisol and platelet 5-ht concentrations might serve as independent biological markers for different subtypes of depression. |
1998-04-30 |
2023-08-12 |
human |
| E Schulz, C Fleischhaker, H W Clement, H Remschmid. Blood biogenic amines during clozapine treatment of early-onset schizophrenia. Journal of neural transmission (Vienna, Austria : 1996). vol 104. issue 10. 1998-04-29. PMID:9503259. |
during long-term treatment, higher serotonin levels were associated with significantly fewer negative symptoms of schizophrenia, whereas higher mhpg levels were correlated with less depression. |
1998-04-29 |
2023-08-12 |
human |
| P Allard, M Norlé. Unchanged density of caudate nucleus dopamine uptake sites in depressed suicide victims. Journal of neural transmission (Vienna, Austria : 1996). vol 104. issue 11-12. 1998-04-29. PMID:9503281. |
in depressive states, theories concerning serotonin and norepinephrine have been dominating, but there are several lines of evidence indicating the involvement of the dopamine system as well, especially in suicidal depression. |
1998-04-29 |
2023-08-12 |
Not clear |
| M F Eddy, G S Walbroeh. Recognition and treatment of obsessive-compulsive disorder. American family physician. vol 57. issue 7. 1998-04-29. PMID:9556649. |
pharmacologic therapy usually includes clomipramine or antidepressant treatment with selective serotonin reuptake inhibitors, but in dosage ranges higher than those typically used in the treatment of depression. |
1998-04-29 |
2023-08-12 |
human |
| D A Sclar, T L Skaer, L M Robison, R S Galin, R F Legg, N L Neme. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. The Journal of clinical psychiatry. vol 59 Suppl 2. 1998-04-28. PMID:9559755. |
herein we describe a retrospective intent-to-treat evaluation designed to compare the natural course of antidepressant utilization and direct health service expenditures for the treatment of a single episode of major depression among patients enrolled in a multistate network-model health maintenance organization and initially prescribed either a tricyclic antidepressant (amitriptyline or nortriptyline) or the serotonin selective reuptake inhibitor (ssri) fluoxetine. |
1998-04-28 |
2023-08-12 |
Not clear |
| F Licata, G Li Volsi, L Ciranna, G Maugeri, F Santangel. 5-Hydroxytryptamine modifies neuronal responses to glutamate in the red nucleus of the rat. Experimental brain research. vol 118. issue 1. 1998-04-15. PMID:9547078. |
extracellular unitary recordings of rn neuronal activity showed that 5-ht application induced a significant and reversible depression of glu-evoked excitations in 85% of the rn units tested. |
1998-04-15 |
2023-08-12 |
rat |
| F Licata, G Li Volsi, L Ciranna, G Maugeri, F Santangel. 5-Hydroxytryptamine modifies neuronal responses to glutamate in the red nucleus of the rat. Experimental brain research. vol 118. issue 1. 1998-04-15. PMID:9547078. |
methysergide application, which prevented the enhancing effects of 5-ht on the background firing, was scarcely effective in antagonising the depression of glu responses. |
1998-04-15 |
2023-08-12 |
rat |
| S Curran, K de Pau. Selecting an antidepressant for use in a patient with epilepsy. Safety considerations. Drug safety. vol 18. issue 2. 1998-04-14. PMID:9512919. |
the selective serotonin [5-hydroxytryptamine; 5-ht] reuptake inhibitors have a low seizure propensity, are well tolerated in overdose and have a favourable adverse effect profile, making them suitable as first line treatments for depression in patients with epilepsy. |
1998-04-14 |
2023-08-12 |
Not clear |
| L Gold, T Back, G Arnold, J Dreier, K M Einhäupl, U Reuter, U Dirnag. Cortical spreading depression-associated hyperemia in rats: involvement of serotonin. Brain research. vol 783. issue 2. 1998-04-13. PMID:9507121. |
we investigated whether the vasoactive neurotransmitter serotonin (5-ht) is involved in cortical spreading depression (csd)-associated hyperemia in the rat. |
1998-04-13 |
2023-08-12 |
rat |